Bank of New York Mellon’s Artelo Biosciences ARTL Stock Holding History

Bank of New York Mellon’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-319	Closed	-$27K	–	4554
2022 Q2	$27K	Sell	319 -2	-0.6%	-$197	﹤0.01%	4459
2022 Q1	$39K	Hold	321	–	–	﹤0.01%	4555
2021 Q4	$45K	Hold	321	–	–	﹤0.01%	4511
2021 Q3	$68K	Hold	321	–	–	﹤0.01%	4391
2021 Q2	$103K	Sell	321 -58	-15%	-$19.8K	﹤0.01%	4214
2021 Q1	$167K	Buy	+379	New	+$162K	﹤0.01%	4099

Other funds holding ARTL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of New York Mellon's ARTL Position: Q3 2022 in Review

Bank of New York Mellon sold out of Artelo Biosciences (ARTL) in Q3 2022, closing a stake of 319 shares — an estimated $27K sold.

Bank of New York Mellon first reported a position in ARTL in Q1 2021 and held it in 6 quarters. The position peaked at $167K in Q1 2021. 9 funds tracked by Wall St. Rank hold ARTL as of Q3 2022.

Bank of New York Mellon reported no remaining Artelo Biosciences position as of Q3 2022 after selling out during the quarter.
Bank of New York Mellon sold 319 Artelo Biosciences shares in Q3 2022, an estimated $27K.
Bank of New York Mellon first reported a position in Artelo Biosciences in Q1 2021 and held it in 6 quarters.
Bank of New York Mellon's Artelo Biosciences position peaked at $167K in Q1 2021.
9 funds tracked by Wall St. Rank held Artelo Biosciences as of Q3 2022.

Based on Bank of New York Mellon's 13F filing for Q3 2022, filed 14 Nov 2022.